Health News

A Pittsburgh start-up company that received an early investment from one of Pennsylvania’s most dynamic resources has entered into an exclusive licensing agreement to help find the cure for Lou Gehrig’s disease, or ALS, Department of Community and Economic Development Secretary Austin Burke announced today.

Read more

Filed under: Pharmacy News
Tags: Pharmacy

Related posts

• “Virtual Patient” helps train pharmacists of the future (0)
  Keele University has developed a “virtual patient” to help train the pharmacists of the future. Read more [tags] Pharmacy News [/tags]
  
  
• “Brain Attack” Gets Fast Tracked at Strong Memorial (0)
  Taking a page out of the playbook developed by cardiologists nearly two decades ago to promote the warning signs and swift treatment for heart attacks, a multidisciplinary team of stroke experts at the University of Rochester Medical Center (URMC) have created a new streamlined triage system at Strong Memorial Hospital's Emergency Department (ED) to provide [...]
  
  
• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Æterna Zentaris commences perifosine Phase 3 registration trial (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. Read [...]
  
  
• Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial (0)
  Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint. Read more [tags] Pharmacy News [/tags]